Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1995-06-01
1997-12-30
Ulm, John
Drug, bio-affecting and body treating compositions
Lymphokine
530351, 514 2, 514 8, 514885, A61K 3819, C07K 1453
Patent
active
057026971
ABSTRACT:
Damage to cells, tissue and other body parts in a mammalian host may be treated by using a colony stimulating factor in conjunction with at least one biological modifier, which may be a free radical scavenger or a metabolic inhibitor. The biological modifier is preferably uric acid, buthionine sulphoximine, vitamin C, aspirin, or nordihydroguaiaretic acid. Such a combination may be used to treat, for example, cancer, infectious diseases, and damage caused by radiation therapy, high oxygen tension, and chemotherapy.
REFERENCES:
patent: 4645830 (1987-02-01), Yasushi et al.
patent: 4677064 (1987-06-01), Mark et al.
patent: 4762705 (1988-08-01), Rubin
patent: 4962091 (1990-10-01), Eppstein et al.
patent: 4980160 (1990-12-01), Goldberg et al.
patent: 4985241 (1991-01-01), Zimmerman et al.
patent: 5002879 (1991-03-01), Bowlin et al.
patent: 5021239 (1991-06-01), Garnick
patent: 5508031 (1996-04-01), Zimmerman et al.
Braun et al., "The In Vitro Development of Cytotoxicity In Response To Granulocyte/Macrophage-Colony-Stimulating Factor or Interferon .gamma. in the Peripheral Blood Monocytes of Patients With Solid Tumors: Modulation by Arachidonic Acid Metabolic Inhibitors," Cancer Immunol. Immunother., 32:55-61 (1990).
Dayer et al., "Cachectin/Tumor Necrosis Factor Stimulates Collagenase and Prostaglandin E.sub.2 Production by Human Synovial Cells and Dermal Fibroblasts," J. Exp. Med., 162:2163-2168 (Dec., 1985).
Delemarre et al., "Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) Reduces Toxoplasmastatic Activity of Human Monocytes Via Induction of Prostaglandin E.sub.2 (PGE.sub.2)," Clin. Exp. Immunol., 102:425-429 (1995).
Desai et al., "Killing of Histoplasma capsulatum by Macrophage Colony Stimulating Factor-Treated Human Monocyte-Derived Macrophages: Role for Reactive Oxygen Intermediates," J. Med. Microbiol., 43:224-229 (1995).
Dinarello et al., "Tumor Necrosis Factor (Cachectin) is an Endogenous Pyrogen and Induces Production of Interleukin 1," J. Exp. Med., 163:1433-1450 (Jun., 1986).
Kharazmi et al., "Modulation of Human Neutrophil and Monocyte Chemotaxis and Superoxide Responses by Recombinant TNF-Alpha and GM-CSF," Immunobiol., 177:363-370 (1988).
Kitagawa et al., "The Respiratory Burst of Granulocytes: Modulation by Inflammatory Mediators and Its Mechanism," Tokai J. Exp. Clin. Med., 13(6):299-305 (1988).
Maeda et al., "Enhanced Antitumor Effect of Recombinant Human Tumor Necrosis Factor in Combination with Recombinant Human Granulocyte Colony-stimulating Factor in BALB/c Mice," Jpn. J. Cancer Res., 84:921-927 (Aug., 1993).
Ohsaka et al., "Effects of Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor on Respiratory Burst Activity of Neutrophils in Patients With Myelodysplastic Syndromes," Clin. Exp. Immunol., 91:308-313 (1993).
Palladino et al., "Tumor Necrosis Factor-Alpha and Interferon-Gamma Induce Neutrophils From Normal and Chronic Granulomatous Disease Patients to Release Superoxide," Ped. Res.,20:302A (1986) (Abstract).
Random House Webster's College Dictionary, Random House, Inc., New York, p. 747 (1992).
Whicher et al., "Cytokines in Disease," Clin. Chem., 36(7):1269-1281 (1990).
Yuo et al., "Tyrosine Phosphorylation and Intracellular Alkalinization Are Early Events in Human Neutrophils Stimulated by Tumor Necrosis Factor, Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte Colony-Stimulating Factor," Biochim. et Biophys. Acta, 1156:197-203 (1993).
Adams et al., "Plasma Glutathione and Glutathione Disulfide in the Rat: Regulation and Response to Oxidative Stress," J. Pharmacol. Exp. Ther., 227(3):749-754 (1983).
Alexander et al., "Synergistic Enhancement by Tumor Necrosis Factor of in Vitro Cytotoxicity from Chemotherapeutic Drugs Targeted at DNA Topisomerase II," Cancer Research, 47:2403-2406 (May 1, 1987).
Almqvist et al., "Treatment of Experimental Canine Endotoxin Shock with Ibuprofen, a Cyclooxygenase Inhibitor," Circulatory Shock, 13:227-232 (1984).
Ames et al., "Uric acid provides an antioxidant defense in humans against oxidant-and readical-caused aging and cancer: A hypothesis," PNAS (USA), 78(11):6858-6862 (Nov., 1981).
Andrews et al., "Differential Potentiation of Alkylating and Platinating Agent Cytotoxicity in Human Ovarian Carcinoma Cells by Glutathione Depletion," Cancer Res., 45:6250-6253 (Dec., 1985).
Aoki et al., "Indomethacin Augments Inhibitory Effect of Interferons on Lymphoproliferative Response," Immunology Letters, 7:321-24 (1984).
Arrick et al., "Inhibition of Glutathione Synthesis Augments Lysis of Murine Tumor Cells by Sulfhydryl-reactive Antineoplastics," J. Clin. Invest., 71(2):258-267 (Feb., 1983).
Aune and Pogue, "Inhibition of Tumor Cell Growth by Interferon-.gamma. is Mediated by Two Distinct Mechanisms Dependent upon Oxygen Tension: Induction of Tryptophan Degradation and Depletion of Intracellular Nicotinamide Adenine Dinucleotide", J. Clin. Invest., 84:863-875 (Sep., 1989).
Bachwich et al., "Tumor Necrosis Factor Stimulates Interleukin-1 and Prostaglandin E.sub.2 Production in Resting Macrophages," Biochemical and Biophysical Research Communications, 136:94-101 (1986).
Badwey and Karnovsky, "Active Oxygen Species And The Functions Of Phagocytic Leukocytes," Ann. Rev. Biochem., 49:695-726 (1980).
Balkwill et al., "Human Tumor Xenografts Treated with Recombinant Human Tumor Necrosis Factor Alone or in Combination with Interferons," Cancer Research, 46:3990-3993 (1986).
Bollag, "Retinoids and Interferon: a new promising combination?" British J. of Haematol., 79(Suppl. 1):87-91 (1991).
Borden, et al., "Lymphokines and Cytokines as Cancer Treatment Immunotherapy Realized," Cancer (Supplement), 65(3):800-814 (Feb. 1, 1990).
Bus and Gibson, "Lipid Peroxidation And Its Role In Toxicology," Rev. Biochm. Toxicol., (Hodgson et al., Eds.)., Elsevier, North Holland, pp. 125-149 (1979).
Cerutti et al., "Membrane-Mediated Chromosomal Damage," Genes And Proteins In Oncogenesis, (Academic Press, NY)., pp. 55-67 (1983).
Chun et al., "Enhancement of Cytotoxic Activity of Natural Killer Cells by Interleukin 2, and Antagonism between Interleukin 2 and Adenosine Cyclic Monophosphate," Scand. J. Immunol. 22:375-81 (1985).
Clark, et al., "Tumor Necrosis Factor and Reactive Oxygen Species: Implications for Free Radical-Induced Tissue Injury," Upjon Symposium/Oxygen Radicals, 122-129 (Apr. 1987).
Crook et al., "Glutathione Depletion as a Determinant of Sensitivity of Human Leukemia Cells to Cyclophosphamide," Cancer Res., 46:5035-5038 (1986).
Das et al., "Free Radicals as Possible Mediators of the Actions of Interferon," J. Free Radicals in Biology and Medicine, 2:183-188 (1986).
DiGuiseppi et al., "The Toxicology Of Molecular Oxygen," CRC Crit. Rev. Toxicol., 12:315-342 (1984).
Dorr et al., "Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine rumor cells," Invest. New Drugs, 4:305-313 (1986).
Dreno et al., "The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of Interferon-.alpha.2a and etretinate," British J. of Dermatol., 125:456-459 (1991).
Ferrante, "Tumor Necrosis Factor Alpha Potentiates Neutrophil Antimicrobial Activity: Increased Fungicidal Activity against Torulopsis glabrata and Candida albicans and Associated Increases in Oxygen Radical Production and Lysosomal Enzyme Release," Infect. Immunity, 57(7):2115-212 2(Jul., 1989).
Freund and Pick, "The Mechanism of Action of Lymphokines IX. The Enzymatic Basis of Hydrogen Peroxide Production by Lymphokine-Activated Macrophages," J. Immunol., 137(4):1312-1318 (Aug. 15, 1986).
Fridovich, "The Biology of Oxygen Radicals," Science, 201:875-880 (1978).
Front et al., "Administered Dose and Tumor Dose of Bleomycin Labeled with Cobalt-57 in Mice and Men," J. Nuclear Med., 31(11):1784-1790 (Nov., 1990).
Gerberick et al., "Relationship Between Pulmonary Inflammation, Plasma Transudation, and Oxygen Metabolite Secretion by Alveolar Macrophages," J. Immunol., 137(1):114-121 (Jul. 1, 1986).
Ghezzi et al., "Role of Reactive Oxygen Intermediates in the Interferon-mediated Depr
Marafino, Jr. Benedict J.
Zimmerman Robert
Blackburn Robert P.
Chiron Corporation
Gass David A.
Mertz Prema
Savereide Paul B.
LandOfFree
Treatment for biological damage using a colony stimulating facto does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment for biological damage using a colony stimulating facto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment for biological damage using a colony stimulating facto will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-199937